Effectiveness of Yavagodhumadi Upanaha Swedana in comperison to Koladi Upanaha Swedana and 1% topical Diclofenac gel in Janu Sandhigatavata (Osteoarthritis of knee)

Evaluation of comparative clinical efficacy of Yavagodhumadi Upanaha Swedana, Koladi Upanaha Swedana and 1% topical Diclofenac sodium gel in the management of Janu Sandhigatavata (Osteoarthritis of knee)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/04/041630

Enrollment

210

Registered

2022-04-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient who are willing to participate in the study and ready to give a written informed consent. 2.Subjects of either sex in the age group of 40 to 60 years. 3.Patients with a diagnosis of knee Osteoarthritis as per American College of Rheumatology clinical and radiographic criteria. 4.Knee Osteoarthritis confirmed by radiological changes as per Kellgren & Lawrence radiological scale of at least grade 2 in X-ray. 5.Osteoarthritis Patients with mean baseline pain intensity of 4 in Visual Analogue Scale (VAS) of 10 in one or both knees.

Exclusion criteria

Exclusion criteria: 1.The subjects who are known to have congenital dysplasia, gouty arthritis, rheumatoid arthritis, psoriatic arthritis and other autoimmune diseases, malignancies, history of any trauma or fractured joint or surgical history to the joint. 2.Patients with gross disability in performing daily normal routine i.e., bedridden subjects or confined to a wheelchair, having any deformity of knee, hip or back altering the gait and posture. 3.Patient who has been administered any chondroprotective drugs, intra-articular injection into the affected knee joint or invasive measures have been performed at the affected joint or systemic medication with corticosteroids during the preceding 3 months. 4.Patients on medication likely to influence evaluation. 5.Pregnant or lactating women 6.Patients with an acute mental disorder, a serious acute organic disease, or any serious comorbidity that made it impossible to participate in the trial interventions.

Design outcomes

Primary

Measure	Time frame
WOMAC questionnaire for pain and physical functionTimepoint: 0- day, 15th day, 30th day	—

Secondary

Measure	Time frame
1. Visual analogue scale (VAS) score for pain and stiffness. 3. 30 (thirty) second chair stand test 4. 40 (forty) meter (4x10 meter) fast-paced walk test 5. Timed up and go test 6. 6 (six) minute walk test 7. Stair climb test 8. Goniometric measurement of the range of movement of knee joint 9. Knee circumference Timepoint: 0- day, 15th day, 30th day	—

Countries

India

Contacts

Public ContactDr ABHISHEK BHATTACHARJEE

Mahatma Gandhi Ayurveda College, Hospital & Research Centre

drshwetaparve@gmail.com9511659185

Outcome results